Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Status:
Completed
Trial end date:
2021-11-18
Target enrollment:
Participant gender:
Summary
A multicenter randomized double-blind placebo parallel control design was used in this
study.60 subjects eligible for inclusion will be randomly assigned to either a low-dose
(0.25ug/kg) medium-dose (0.5ug/kg) high-dose (2.0ug/kg) experimental drug group or a control
group (placebo) at a ratio of 1:1:1:1.After randomization, subjects received the experimental
drug or placebo once a day, intravenously, on day 2 to 7, 12 hours and 4 hours after
PCI.Ninety days after PCI were observed.